Cargando…

Co-Expression of IL-7 Improves NKG2D-Based CAR T Cell Therapy on Prostate Cancer by Enhancing the Expansion and Inhibiting the Apoptosis and Exhaustion

Chimeric antigen receptor (CAR) T-cell therapy is a promising approach in treating solid tumors but the therapeutic effect is limited. Prostate cancer is a typical solid malignancy with invasive property and a highly immunosuppressive microenvironment. Ligands for the NKG2D receptor are primarily ex...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Cong, Zhou, Ying, Li, Zhenlong, Farooq, Muhammad Asad, Ajmal, Iqra, Zhang, Hongmei, Zhang, Li, Tao, Lei, Yao, Jie, Du, Bing, Liu, Mingyao, Jiang, Wenzheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409228/ https://www.ncbi.nlm.nih.gov/pubmed/32698361 http://dx.doi.org/10.3390/cancers12071969

Ejemplares similares

Suppression of 4.1R enhances the potency of NKG2D-CAR T cells against pancreatic carcinoma via activating ERK signaling pathway
por: Gao, Yaoxin, et al.
Publicado: (2021)

CD19-CAR-T Cells Bearing a KIR/PD-1-Based Inhibitory CAR Eradicate CD19(+)HLA-C1(−) Malignant B Cells While Sparing CD19(+)HLA-C1(+) Healthy B Cells
por: Tao, Lei, et al.
Publicado: (2020)

β2-Adrenergic Receptor Mediated Inhibition of T Cell Function and Its Implications for CAR-T Cell Therapy
por: Farooq, Muhammad Asad, et al.
Publicado: (2023)

Isoprenaline and salbutamol inhibit pyroptosis and promote mitochondrial biogenesis in arthritic chondrocytes by downregulating β-arrestin and GRK2
por: Ajmal, Iqra, et al.
Publicado: (2022)

NKG2A is a NK cell exhaustion checkpoint for HCV persistence
por: Zhang, Chao, et al.
Publicado: (2019)

T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies
por: Tang, Lu, et al.
Publicado: (2021)

An overview of viral mutagenesis and the impact on pathogenesis of SARS-CoV-2 variants
por: Khan, Muhammad Zafar Irshad, et al.
Publicado: (2022)

A summary of current NKG2D-based CAR clinical trials
por: Curio, Sophie, et al.
Publicado: (2021)

T cell senescence and CAR-T cell exhaustion in hematological malignancies
por: Kasakovski, Dimitri, et al.
Publicado: (2018)

Mechanisms of CAR T cell exhaustion and current counteraction strategies
por: Zhu, Xiaoying, et al.
Publicado: (2022)

Exhaustion of CAR T cells: potential causes and solutions
por: Kouro, Taku, et al.
Publicado: (2022)

DAP10 integration in CAR-T cells enhances the killing of heterogeneous tumors by harnessing endogenous NKG2D
por: Li, Shanglin, et al.
Publicado: (2022)

Differential expression of inhibitory receptor NKG2A distinguishes disease‐specific exhausted CD8(+) T cells
por: Chen, Xiangyu, et al.
Publicado: (2022)

Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion
por: Gumber, Diana, et al.
Publicado: (2022)

Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells
por: Huang, Yue, et al.
Publicado: (2022)

Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy
por: Bulliard, Yannick, et al.
Publicado: (2023)

NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma
por: Leivas, Alejandra, et al.
Publicado: (2021)

Polyclonal Expansion of NKG2C(+) NK Cells in TAP-Deficient Patients
por: Béziat, Vivien, et al.
Publicado: (2015)

NKG2D(+)CD4(+) T Cells Kill Regulatory T Cells in a NKG2D-NKG2D Ligand- Dependent Manner in Systemic Lupus Erythematosus
por: Yang, Di, et al.
Publicado: (2017)

Manufacturing NKG2D CAR-T cells with piggyBac transposon vectors and K562 artificial antigen-presenting cells
por: Tay, Johan C.K., et al.
Publicado: (2021)

GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy
por: Fernández, Lucía, et al.
Publicado: (2019)

c-Jun overexpression in CAR T cells induces exhaustion resistance
por: Lynn, Rachel C., et al.
Publicado: (2019)

Dynamic chromatin regulatory landscape of human CAR T cell exhaustion
por: Gennert, David G., et al.
Publicado: (2021)

Combination of 4-1BB and DAP10 promotes proliferation and persistence of NKG2D(bbz) CAR-T cells
por: Wei, Cheng, et al.
Publicado: (2022)

BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells
por: Seo, Hyungseok, et al.
Publicado: (2021)

Lenalidomide improves NKG2D-based CAR-T cell activity against colorectal cancer cells invitro
por: Zarei, Mahdi, et al.
Publicado: (2023)

S256: HLA-E/NKG2A CHECKPOINT DRIVES MULTIPLE MYELOMA RESISTANCE TO CAR-NK THERAPY
por: Encinas, Jessica, et al.
Publicado: (2023)

The NK cell checkpoint NKG2A maintains expansion capacity of human NK cells
por: Kaulfuss, Meike, et al.
Publicado: (2023)

piggyBac system to co-express NKG2D CAR and IL-15 to augment the in vivo persistence and anti-AML activity of human peripheral blood NK cells
por: Du, Zhicheng, et al.
Publicado: (2021)

Consensus report: mutagenicity and carcinogenicity of car exhausts and coal combustion emissions.
Publicado: (1983)

Adipose Stromal Cell Expansion and Exhaustion: Mechanisms and Consequences
por: Eckel-Mahan, Kristin, et al.
Publicado: (2020)

Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity
por: Zhang, Congcong, et al.
Publicado: (2021)

Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy
por: Ghasemi, Reza, et al.
Publicado: (2016)

New prospects on the NKG2D/NKG2DL system for oncology
por: Ullrich, Evelyn, et al.
Publicado: (2013)

Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy
por: Ding, Hui, et al.
Publicado: (2018)

Soluble NKG2D ligand promotes MDSC expansion and skews macrophage to the alternatively activated phenotype
por: Xiao, Gang, et al.
Publicado: (2015)

Current Progress in CAR-T Cell Therapy for Solid Tumors
por: Ma, Shuo, et al.
Publicado: (2019)

Transient “rest” restores functionality in exhausted CAR-T cells via epigenetic remodeling
por: Weber, Evan W., et al.
Publicado: (2021)

Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML
por: Nixdorf, D., et al.
Publicado: (2023)

Membrane-bound IL-2 improves the expansion, survival, and phenotype of CAR Tregs and confers resistance to calcineurin inhibitors
por: Kremer, Jakob, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4at77m7686dg0310kttjcb0o2l